Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.95
+1.09 (0.53%)
AAPL  259.01
-1.57 (-0.60%)
AMD  199.71
-3.66 (-1.80%)
BAC  52.13
-0.64 (-1.21%)
GOOG  309.12
+5.56 (1.83%)
META  648.93
+4.15 (0.64%)
MSFT  397.21
-1.25 (-0.31%)
NVDA  187.66
-0.24 (-0.13%)
ORCL  151.82
-4.72 (-3.02%)
TSLA  407.94
-3.77 (-0.92%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.